Scientific Temper

Biotechnology

Stem cells and their uses: therapy, iPS cells, cloning and transplants

Builds on: The cell (stem cells and potency).

In a nutshell

Stem cell therapy uses stem cells, or cells grown from them, to replace cells the body has lost or cannot make properly. It is also changing how new drugs are tested.

  1. Find healthy stem cells: from the patient, from a donor whose tissue type (HLA) matches, or by reprogramming an ordinary adult cell into an iPS cell.
  2. Grow the cells that are needed: blood cells, corneal cells, nerve cells, heart muscle.
  3. Put them back, or test drugs on them: regenerative medicine on one side, faster and more personal drug development on the other.

Where things stand (Nov 2026): bone marrow (haematopoietic) stem cell transplants are established treatment; Japan approved the first iPS-cell products in March 2026; organs from gene-edited pigs are in clinical trials in the US.

"Second patient reported free of HIV after receiving stem cell therapy"

In 2019 a man in London, being treated for a blood cancer, received bone marrow stem cells from a donor whose cells lacked the CCR5 receptor, the lock HIV uses to enter immune cells. After the transplant, the virus could no longer be found in his body. Stem cells had rebuilt his immune system with new cells that HIV could not enter. What exactly did the doctors do, and why can't everyone with HIV be treated this way?

In the last topic we classified cells by their ability to become other kinds of cell. Stem cells could; differentiated cells could only divide. This topic asks what we can do with that ability.

What stem cell therapy is

Cell therapy means using cells to produce a therapeutic effect. Stem cell therapy uses stem cells, or cells grown from them. (Gene therapy, which comes later, delivers genes rather than cells.) Stem cells are used in two broad ways:

  • Regenerative medicine: regenerating cells, tissues or organs that are lost or damaged. This includes tissue engineering and the long-term hope of replacing conventional organ transplants.
  • Drug development: growing human cells in the laboratory to see how they respond to a drug, which can shorten and sharpen the long road from discovery to medicine.

Damaged cells and defective cells

Why would a body need new cells? There are two kinds of problem, and they need different solutions.

  • Damaged cells. Healthy cells are lost through ageing, injury or long exposure to harmful substances. The body's own stem cells may still be normal. Example: the clear outer layer of the eye, the cornea, can be damaged by injury or chemical burns; stem cells at its rim (the limbus) normally renew it.
  • Defective cells. The stem cells themselves are faulty and keep producing faulty cells. Here the patient's own stem cells cannot be used as they are.

Blood: the classic example of defective cells

Blood is made in the bone marrow by haematopoietic stem cells ("haem" refers to blood), adult stem cells that produce red blood cells, the many kinds of white blood cells, and platelets. Red blood cells carry oxygen on haemoglobin, an iron-containing protein. If they cannot do this well, every cell in the body gets less oxygen, less cellular respiration and less energy. Two inherited disorders show the two ways this can go wrong:

Beta-thalassaemiaSickle cell disease
What goes wrongToo little normal haemoglobin is made, so red cells are too few and too weakAbnormal haemoglobin makes red cells stiff and sickle-shaped; they block small blood vessels and break down early
Conventional careRegular blood transfusions, often every few weeks, for lifePain management, transfusions, drugs; complications through life
Possible cureReplace the faulty blood-forming stem cells: a bone marrow transplant from a matching donor, or gene therapy on the patient's own stem cells (covered later)

Sickle cell disease is a particular burden among India's tribal communities, which is why India's gene therapy for it, which comes up under gene therapy, is named Birsa 101, after Birsa Munda.

Bone marrow transplants and the HLA match

A bone marrow (haematopoietic stem cell) transplant replaces a patient's faulty blood-forming stem cells with healthy ones from a donor. The difficulty is finding the right donor. Our cells carry surface proteins called HLA (human leukocyte antigens) that act like an identity card. If the donor's HLA does not closely match the patient's, the immune system treats the new cells as foreign and attacks them, or the donor cells attack the patient. Every transplant, of marrow or of any organ, begins with an HLA match.

  • Siblings are the best chance, because they inherit their HLA genes from the same two parents. Even so, each brother or sister has only about a one-in-four chance of being a full match.
  • Donor registries record the HLA types of volunteers so that an unrelated match can be found. The shortage of organs and marrow is largely a shortage of information about who could donate.
  • A saviour sibling is a child conceived by IVF, with embryos tested before implantation so that the chosen embryo is both free of the disease and an HLA match for an ill brother or sister. India's first case was in Ahmedabad: a girl born in 2018 donated bone marrow in 2020 to her brother, who had thalassaemia major, and he no longer needed transfusions. The practice raises real ethical questions, because a child is created partly to serve as a donor.

Cost is a barrier too. Schemes such as the Thalassemia Bal Sewa Yojana, funded through Coal India's corporate social responsibility programme, help poor families pay for marrow transplants.

What India allows

India's National Guidelines for Stem Cell Research (ICMR and DBT, 2017) are strict. Stem cell transplantation for approved blood disorders is established treatment. Any other use of stem cells in patients is investigational: it is permitted only within an approved clinical trial, and offering it outside one is unethical and treated as malpractice. The guidelines were written to curb clinics selling unproven "stem cell cures".

iPS cells: making embryonic-like cells from adult cells

The ideal donor is yourself: your own cells carry your own HLA, so your body will not reject them. But your embryonic stem cells, the pluripotent cells that could become anything, were used up when you were a ball of a hundred cells. Your adult stem cells may be damaged or defective. Is there a way back?

Recall that every cell carries the same instruction manual. A skin cell and an embryonic cell have the same DNA. The difference lies in which instructions each one is using. Think of two cities with the same constitution: a steel town that makes only steel, and a metropolis with every kind of industry. The constitution is the same; what differs is what each city has switched on. So if we could switch a skin cell back to the "metropolis" state, it should behave like an embryonic stem cell again.

This is exactly what Shinya Yamanaka showed in 2006, first with mouse cells and then with human cells. By switching on a handful of genes that control development, he turned ordinary adult cells into induced pluripotent stem cells (iPS cells): "induced" because they are made, "pluripotent" because they can become almost any cell type. Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine with John Gurdon, whose frog experiments (below) had first shown that an adult cell's DNA can be reset.

Advantages of iPS cellsLimitations
Made from the patient's own cells, so rejection is not expectedMaking, checking and growing them takes months and is expensive
No embryos are used, avoiding the main ethical objection to embryonic stem cellsReprogrammed cells can carry a risk of uncontrolled growth (tumours), so safety testing is essential
Can supply cells the body cannot replace, such as neuronsIf the patient's own genes are faulty, the iPS cells carry the same fault unless it is corrected

To save time and cost, many programmes use iPS cells from carefully chosen healthy donors rather than from each patient, accepting some need for HLA matching.

Where iPS cells are being used

  • Eye diseases: iPS-derived cells have been transplanted to repair the cornea and the retina in Japanese trials.
  • Parkinson's disease: in Parkinson's, the brain gradually loses the neurons that produce dopamine, a chemical messenger needed for controlling movement. Neurons do not normally regenerate, so lost ones are not replaced. iPS cells can be guided to become dopamine-producing cells and implanted in the brain. In March 2026 Japan gave conditional, time-limited approval to such a product (Amchepry, Sumitomo Pharma, based on a Kyoto University trial), the world's first approved iPS-cell therapy. A second iPS product, sheets of heart muscle cells for severe heart failure (ReHeart), was approved at the same time.
  • Blood: iPS cells can be turned into blood-forming stem cells and blood cells.

"Conditional" matters: the products were approved on small trials and must prove their safety and benefit through follow-up studies over several years.

Testing drugs on stem cells

A new medicine usually acts on a protein in our cells: one that is faulty, too abundant, too scarce or missing. Developing it takes many years because of the stages it must pass through:

  1. Discovery: identify the target protein and design molecules that act on it.
  2. Pre-clinical testing: in cells and in laboratory animals, mainly for safety.
  3. Phase I trial: a small group of people, usually healthy volunteers, to check safety and dose.
  4. Phase II trial: patients with the disease, to check whether it works and its side effects, often against a control group given a placebo, a dummy treatment, because belief alone can make people feel better.
  5. Phase III trial: large numbers of patients, to confirm benefit and catch rarer harms; then regulatory approval and continued monitoring after the drug is on sale.

iPS cells offer a shortcut at the early stages. Heart, liver or nerve cells grown from a person's iPS cells are real human cells, so scientists can watch how they respond to a candidate drug before it ever reaches a patient. Because the cells can come from different people, they also show why a drug works for one person and not another. This is one route to precision medicine, in which treatment is matched to the individual. It speeds up and sharpens testing; it does not remove the need for clinical trials.

Cloning: somatic cell nuclear transfer

Suppose a farmer has one exceptional sheep and wants an exact copy. The animal is an adult, so it has no embryonic cells left. Cloning gets around this using the egg cell.

An egg is the largest cell in the body, packed with the nutrients and machinery that turn a fertilised egg into an embryo. A sperm contributes little more than DNA. So:

  1. Take an egg from a donor and remove its nucleus (enucleation).
  2. Take a body cell, a somatic cell, from the animal to be copied, and transfer its nucleus into the empty egg.
  3. The egg's machinery resets that adult DNA, and the egg begins to divide like a fertilised egg, forming an embryo that is implanted in a surrogate mother.

Hence the name somatic cell nuclear transfer (SCNT). John Gurdon first cloned frogs this way in the early 1960s. Dolly the sheep, born in 1996 at the Roslin Institute in Scotland, was the first mammal cloned from an adult cell. The success rate is very low, because most reconstructed eggs fail to develop. Note one detail: the clone's nuclear DNA comes from the animal being copied, but its mitochondrial DNA comes from the egg donor.

Cloning to produce a whole animal is reproductive cloning. Making cloned embryos only to obtain stem cells is therapeutic cloning. Human reproductive cloning is prohibited in India and most countries.

Transplants classified by donor

TypeDonorExampleRejection riskMain drawback
AutologousThe patientOwn stem cells; iPS cells from own cellsLowestSlow; not possible if the patient's cells are defective
AllogeneicAnother personSibling or registry donor; saviour siblingPresent; needs HLA matching and immune-suppressing drugsShortage of matching donors
XenogeneicAnother speciesGene-edited pig kidney or heartHighestStrong immune attack; risk of animal viruses

Xenotransplantation: organs from pigs

The body rejects the unfamiliar, and an organ from another species is as unfamiliar as it gets. Pigs are the favoured donors because their organs are a similar size to ours, they breed quickly and they are already farmed. To make pig organs acceptable, scientists edit the pig's genes with CRISPR: removing pig genes that trigger immediate human rejection, adding human genes that calm the immune response, and inactivating viruses hidden in the pig's own DNA.

  • Two men in the US received gene-edited pig hearts, in 2022 and 2023; each survived a matter of weeks.
  • Kidneys have gone further. Tim Andrews, who received a pig kidney with 69 gene edits in January 2025, lived without dialysis for a record 271 days before it had to be removed in October 2025.
  • In 2025 the US regulator, the FDA, cleared the first formal clinical trials of gene-edited pig kidneys, by the companies eGenesis and United Therapeutics.

These are pig organs that have been genetically modified, not human organs grown inside pigs. Growing human organs inside animals, starting from human stem cells, is a separate idea that remains at the research stage.

Organoids and bioprinting: models before replacements

Two further uses of stem cells are often grouped with transplantation, although most of their value today lies elsewhere. An organoid is a small three-dimensional cluster grown from stem cells that organises itself into some of the structure of a real organ: a few millimetres of gut lining, kidney tubules, or brain tissue with distinct cell layers. It has no blood supply and is far simpler than the organ it resembles, so it does not replace anything. What it offers is a human tissue to experiment on, which is why organoids are used to test drugs, to study how a virus infects human cells, and to model a patient's own disease by growing the organoid from that patient's cells.

Bioprinting approaches the problem from the engineering side, depositing living cells in a supporting gel layer by layer to build a tissue to a design, rather than waiting for cells to arrange themselves. Simple flat or avascular tissues such as skin and cartilage are the realistic targets; the obstacle to printing a whole organ is the same one organoids face, namely that thick tissue dies without a blood supply, and printing a working network of fine vessels remains unsolved. Both, for now, are better described as tools for research and for small repairs than as a route to organs on demand.

Choosing a source of healthy cells

ProblemSourceWhy
Cells damaged, own stem cells normalPatient's own adult stem cells (autologous)No rejection
Own stem cells defectiveHLA-matched donor: sibling, registry, saviour siblingHealthy cells; rejection controlled by matching
No suitable stem cells in the body (e.g. neurons)iPS cells, from the patient or a matched donorPluripotent cells without an embryo
Whole organ needed, no human donorGene-edited pig organ (xenogeneic)Supply; still experimental

Recent developments

First patient treated with an iPS-cell therapy for Parkinson's disease

Japan's health ministry gave conditional, time-limited approval on 6 March 2026 to two products made from induced pluripotent stem cells: Amchepry (Sumitomo Pharma), in which iPS cells from healthy donors are turned into the precursors of dopamine-producing neurons and transplanted into the brain in Parkinson's disease, and ReHeart (Cuorips), sheets of heart-muscle cells for severe heart failure. Sumitomo Pharma said on 30 October 2026 that the first transplant under that approval had been carried out at Kyoto University Hospital.

Why it matters: These are the first iPS-cell products anywhere cleared for sale, about twenty years after the reprogramming work that won Yamanaka the Nobel Prize in 2012, and they test the central claim of the iPS route: that replacement cells can be supplied without using an embryo. The approval is conditional and time-limited, which means efficacy is not yet established. The companies must keep following patients for seven years before full approval can be considered, so this is the beginning of the evidence and not the end of it.

Remember: iPS cells are ordinary adult cells reprogrammed to an embryonic-like state, so no embryo is destroyed and the cells can come from a donor rather than the patient. Amchepry supplies the dopamine-producing neurons that Parkinson's disease destroys; the Kyoto University trial behind it treated seven patients aged 50 to 69 with 5 or 10 million cells. Conditional approval is not proof of cure.

Source: Sumitomo Pharma announcement, reported by AFP, November 2026

Last-month notes
  • Stem cell therapy: two uses, regenerative medicine and drug testing. Cell therapy delivers cells; gene therapy delivers genes.
  • Haematopoietic stem cells (bone marrow) make all blood cells. Thalassaemia: too little haemoglobin. Sickle cell disease: abnormal, sickle-shaped red cells. Birsa 101: India's gene therapy for sickle cell disease.
  • HLA match decides transplant success; each sibling has about a 1 in 4 chance of a full match. Saviour sibling: IVF with embryo testing; India's first case, Ahmedabad (born 2018, transplant 2020).
  • ICMR–DBT guidelines (2017): only haematopoietic stem cell transplantation for approved blood disorders is established; all other stem cell use only in approved trials.
  • iPS cells: Yamanaka (2006); Nobel 2012 with Gurdon. Japan, March 2026: first approved iPS products (Parkinson's, Amchepry; heart sheets, ReHeart), conditional and time-limited.
  • SCNT: nucleus of a somatic cell into an enucleated egg. Gurdon's frogs (1960s); Dolly (1996, Roslin), first mammal from an adult cell. Clone's mitochondrial DNA comes from the egg donor.
  • Autologous (self) < allogeneic (same species) < xenogeneic (other species) in rejection risk. Pig kidney: record 271 days (Tim Andrews, 2025); US clinical trials cleared in 2025.

Statements to watch for

  • iPS cells are made from adult cells; no embryo is destroyed.
  • Parkinson's is the loss of dopamine-producing neurons in the brain, not a disease of motor neurons.
  • The cornea is the clear front surface of the eye, not the lens.
  • Siblings are often, not always, an HLA match.
  • Xenotransplants so far use gene-edited pig organs, not human organs grown in pigs.
  • An organoid is a model grown from stem cells, not a transplantable organ; bioprinted tissue is limited by the lack of a blood supply.

Revise and apply

Activities to check your understanding, not new content. Answer first, then press Check or Show answers. Multiple-choice questions are original, in the UPSC style, not past UPSC questions. A printable workbook with all activities is on the theme page.

Complete the mind map

Type the missing words, then check.

Stem cells and their uses
Two uses
Replacing lost cells: medicine
Testing new
Blood
Bone marrow stem cells:
Too little haemoglobin:
Sickle-shaped red cells: sickle cell
Finding a donor
Match the proteins
IVF child chosen as a match: saviour
Making stem cells
Adult cell reprogrammed: cell
Nucleus into an empty egg: somatic cell nuclear
Fill in the blanks
  1. Before any transplant, doctors check that the donor's matches the patient's, to reduce rejection.
  2. iPS cells were first made by , who shared the 2012 Nobel Prize with John Gurdon.
  3. In a clone made by nuclear transfer, the mitochondrial DNA comes from the donor.
  4. A transplant from another species is called .
  5. In Parkinson's disease, the brain loses neurons that produce .
Match the transplant to its donor
  1. Autologous
  2. Allogeneic
  3. Xenogeneic
True or false? Correct the false ones
  1. Making iPS cells requires destroying a human embryo.
  2. In India, stem cells may be used in patients outside clinical trials only for approved blood disorders.
  3. A brother or sister is always a perfect HLA match.
  4. Dolly the sheep was the first animal ever cloned.
  5. Recent xenotransplants used human organs grown inside pigs.
Decode the headline

"Japan grants conditional approval to world's first iPS-cell therapy for Parkinson's disease." (a) What is an iPS cell and what is it made from? (b) Why are stem cells needed for Parkinson's at all? (c) What does "conditional" approval mean here?

UPSC-style question 1

Consider the following statements about induced pluripotent stem (iPS) cells:

  1. They are obtained from the inner cell mass of an early embryo.
  2. They can be made from a patient's own adult cells.
  3. They can be guided to become nerve cells.

Which of the statements given above is/are correct?

UPSC-style question 2

In reproductive cloning by somatic cell nuclear transfer, the cloned animal's nuclear DNA comes from:

Write in about 50 words

Why are iPS cells considered a breakthrough for regenerative medicine? Answer in about 50 words.

0 words
Write in about 50 words

Xenotransplantation could ease the shortage of organs. What stands in its way? Answer in about 50 words.

0 words

The next question Reprogramming a skin cell into an iPS cell meant switching certain instructions back on. To understand how that is possible, and how we can later read and edit those instructions, we have to go inside the nucleus and look at DNA itself.